UroGen drops 20% as FDA releases docs in advance of AdCom meeting

1 month ago 3

• Healthcare
• On the Move

JHVEPhoto

UroGen (NASDAQ:URGN) has fallen ~20% in Friday trading after the U.S. FDA released a briefing document in advance of an Oncologic Drugs Advisory Committee meeting on May 21 to discuss an NDA for UGN-102 (mitomycin) for recurrent low-grade intermediate-risk non-muscle invasive

Recommended For You

More Trending News

See More »

1. Homepage
2. Politics
3. UroGen drops 20% as FDA releases docs in advance of AdCom meeting